NCT05676684View on ClinicalTrials.gov

Dapagliflozin With or Without Spironolactone for HFpEF

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2024

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

Dapagliflozin

A: Dapagliflozin 10 mg once daily

DRUG

Spironolactone + Dapagliflozin

C: Dapagliflozin 10 mg once daily plus Spironolactone 25mg/every other day or 25mg/day (can be adjusted according to potassium and renal function)

Trial Locations (2)

4434-502

Unidade Local de Saúde Gaia/Espinho, Porto

4200-319

Centro Hospitalar Universitário São João, Porto

All Listed Sponsors
collaborator

Centro Hospitalar De São João, E.P.E.

OTHER

collaborator

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

OTHER_GOV

lead

Universidade do Porto

OTHER